重组人血管内皮抑制素联合化疗对晚期肿瘤的疗效及安全性回顾性研究

目的观察重组人血管内皮抑制素（恩度）联合化疗方案对多种晚期肿瘤的有效性及安全性。方法回顾性分析从2007年11月-2010年10月本科收治的60例晚期肿瘤患者的临床资料，提取实验室检查、治疗周期、治疗方案、疗效评价、随访资料，比较联合恩度组与单用化疗组患者之间近期疗效、不良反应、生活质量、生存时间的差异。结果与单用化疗组（C组）相比，恩度联合组（EC组）提高了临床获益率，改善了生活质量，一定程度上延长了生存时间，且不增加化疗不良反应。结论恩度联合化疗能显著提高晚期肿瘤患者的生活质量和临床获益率，同时没有明显增加化疗的不良反应。

Observation of The Effects of Recombinant Human Endostatin Combined with Chemotherapy in The Treatment of Various Advanced Malignant Tumor

Objective To observe the validity and safety of recombinant human endostatin（Endostar） combined with chemotherapy for the treatment of the advanced malignant tumor. Methods The clinical date were analyzed in sixty cases of pathology or cytology confirmed advanced cancer with laboratory examination, treatment cycles, efficacy evaluation, adverse reactions, quality of life（ QOL）, survival time from November, 2011 to October, 2010. Results Endostar combined with chemotherapy group can improve the QOL while without add the chemotherapy adverse effect versus the chemotherapy group. Conclusions Endostar combined with chemotherapy for the treatment of advanced tumor had good effects, while there＇s no significant increase in toxicity comparing to chemotherapy,which deserves further research.